Hofseth International AS ("HI"), a close associate of Hofseth Biocare ASA's (the "Company") board member Roger Hofseth, has notified the Company that HI.
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and.
29.08.2022 - Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo Bioactive Peptides. Summary Highlights of the FDA’s NDI Process for HBC and what it . Seite 1
Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for.
HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of.